Iscar for Supplemental Care in Stage IV Lung Cancer

This study has been completed.

Sponsor:

Information provided by:

National Center for Complementary and Integrative Health (NCCIH)

ClinicalTrials.gov Identifier:

NCT00079794

First received: March 15, 2004

Last updated: January 23, 2008

Last verified: January 2008

History of Changes

Purpose

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Condition	Intervention	Phase
Lung Cancer	Drug: Iscar Drug: mistletoe	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	Iscar for Supplemental Care in Stage IV Lung Cancer

Resource links provided by NLM:

Genetics Home Reference related topics: lung cancer

MedlinePlus related topics: Lung Cancer

U.S. FDA Resources

Further study details as provided by National Center for Complementary and Integrative Health (NCCIH):


Estimated Enrollment:	36
Study Start Date:	September 2001
Study Completion Date:	February 2004
Primary Completion Date:	February 2004 (Final data collection date for primary outcome measure)

Detailed Description:

See Brief Summary

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Stage IV NSCLC patients who receive standard chemotherapy

Exclusion criteria:

Known allergy to Viscum Album L.
Concomitant use of other mistletoe products
Concomitant use of mushroom glucan and proteoglycan extracts
Concomitant use of thymus extract products
Inability to self-report quality of life utilizing assessment tools
Ongoing steroid or ACTH therapy
Co-morbid immunocompromised state
Pregnancy
Participation in other clinical trials

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00079794

Locations


United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107

Sponsors and Collaborators

National Center for Complementary and Integrative Health (NCCIH)

Investigators


Principal Investigator:	Steven Rosenzweig, MD	Jefferson Medical College of Thomas Jefferson University

More Information


ClinicalTrials.gov Identifier:	NCT00079794 History of Changes
Other Study ID Numbers:	R21AT001020-01 ( U.S. NIH Grant/Contract ) Rosenzweig
Study First Received:	March 15, 2004
Last Updated:	January 23, 2008

Keywords provided by National Center for Complementary and Integrative Health (NCCIH):


lung cancer herbal medicine non-small cell cancer Iscar mistletoe

Additional relevant MeSH terms:


Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site	Neoplasms Lung Diseases Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 22, 2017

To Top